AnteoTech is pleased to advise that it has renewed its contract with leading healthcare diagnostic partner Ellume Ltd. (“Ellume”) for the supply of AnteoBind to be used in Ellume’s range of tests.
Ellume is an Australia-based diagnostics company that develops, manufactures and commercialises high-performance connected products for health professionals and consumers. Most recently, Ellume became the first over-the-counter fully at-home diagnostic test for COVID-19 to be granted authorisation from the US Food and Drug Administration. This test utilises AnteoTech’s unique AnteoBind technology.
AnteoTech and Ellume have been in partnership since 2016, and this contract renewal highlights the strong relationship between the two companies. The terms of the contract are commercial-in-confidence and reflect the commercial positions of both companies having undergone significant transformation over the past five years.
AnteoTech CEO Derek Thomson said, “We are very pleased to have renewed our sales contract with Ellume. Ellume has been a longstanding customer and have used our AnteoBind technology to great effect. We look forward to supporting Ellume to achieve their ambition of a large volume of test sales in the US market in 2022 and beyond.”